Ordering RecommendationRecommendations when to order or not order the test. May include related or preferred tests.
Aid in detection of prostate cancer in men age 50 and older when used in conjunction with a digital rectal exam. May also be used as an aid to manage and monitor prostate cancer patients.
MnemonicUnique test identifier.
PSA COMP
MethodologyProcess(es) used to perform the test.
Chemiluminescent Immunoassay
PerformedDays of the week the test is performed.
Sun
ReportedExpected turnaround time for a result, beginning when ARUP has received the specimen.
1-8 days
New York DOH Approval StatusIndicates test has been approved by the New York State Department of Health.
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect
Plain red or serum separator tube.
Specimen Preparation
Transfer 1.0 mL serum to an ARUP standard transport tube. (Min: 0.5 mL)
Storage/Transport Temperature
Refrigerated.
Unacceptable Conditions
Hemolyzed specimens. Any specimens other than serum.
Reference IntervalNormal range/expected value(s) for a specific disease state. May also include abnormal ranges.
0 - 3.6 ng/mL
Interpretive DataBackground information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
This test uses the Siemens' ADVIA Centaur cPSA methodology, which is FDA approved for use as an aid in the detection of prostate cancer in men age 50 and older when used in conjunction with a digital rectal exam. This methodology is also approved as an aid in the management/monitoring of prostate cancer patients. Results obtained with different assay methods or kits cannot be used interchangeably. Prostatic biopsy is required for the diagnosis of cancer. cPSA is generally not elevated in healthy men or with non-prostatic carcinoma. cPSA concentrations may be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. Prostate cancer patients under treatment with antiandrogens and LHRH agonists and antagonists may exhibit markedly reduced levels of cPSA. Care should be taken when interpreting values from these individuals.
No compliance statements are in use for this test.
NoteAdditional information related to the test.
Hotline History
N/A
CPT CodesThe American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
AliasesOther names that describe the test. Synonyms.
Chat
Feedback
